STOCK TITAN

Bio-Techne Corp (TECH) SVP option exercise and share withholding

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bio-Techne Corp SVP and General Counsel Shane Bohnen exercised stock options for 448 shares of common stock on 2026-07-23 at an exercise price of 47.6000 per share, converting an option on 448 shares into directly held stock. To satisfy the exercise price or related tax obligations, 344 shares of common stock were withheld at 71.7700 per share. He continues to hold multiple option and stock-unit awards, including stock options over 8,944 shares at a 66.9700 exercise price expiring 2027-08-05 and 3,460 shares at 120.4600 expiring 2028-08-06. The filing indicates these transactions were not made under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Bohnen Shane
Role SVP - General Counsel
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1 448 $0.00 $0.00
Exercise Common Stock 448 $47.60 $21K
Exercise Price or Tax Liability Common Stock 344 $71.77 $25K
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F1 -- -- --
holding Stock Option (Right to Buy) F2 -- -- --
holding Stock Option (Right to Buy) F3 -- -- --
holding Stock Option (Right to Buy) F5 -- -- --
holding Restricted Stock Units F4, F6 -- -- --
holding Performance Restricted Stock Units F4, F7 -- -- --
holding Performance Stock Option (Right to Buy) F7 -- -- --
holding Performance Restricted Stock Units F4, F8 -- -- --
holding Restricted Stock Units F4, F9 -- -- --
holding Stock Option (Right to Buy) F10 -- -- --
holding Performance Restricted Stock Units F4, F11 -- -- --
holding Restricted Stock Units F4, F12 -- -- --
holding Stock Option (Right to Buy) F13 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 67,527 shares (Direct); Common Stock — 7,353 shares (Direct); Restricted Stock Units — 10,383 shares (Direct); Performance Restricted Stock Units — 28,806 shares (Direct); Performance Stock Option (Right to Buy) — 12,924 shares (Direct)
Footnotes (13)
  1. F1. Fully exercisable.
  2. F2. Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024.
  3. F3. Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
  4. F4. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  5. F5. Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
  6. F6. 49 restricted stock units vest on 8/15/2026.
  7. F7. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  8. F8. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  9. F9. 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
  10. F10. Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
  11. F11. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  12. F12. 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
  13. F13. Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
Options exercised into common stock 448.0000 shares Stock options for common stock exercised at 47.6000 per share on 2026-07-23
Exercise price for options exercised 47.6000 per share Exercise price for 448.0000 stock options converted into common stock
Shares withheld for taxes or exercise price 344.0000 shares Common shares withheld at 71.7700 per share to pay exercise price or tax liability
Withholding price per share 71.7700 per share Price used for withholding 344.0000 shares coded as tax or exercise-price payment
Option position expiring 2027-08-05 8944.0000 shares Underlying shares for a stock option with a 66.9700 exercise price expiring 2027-08-05
Option position expiring 2028-08-06 3460.0000 shares Underlying shares for a stock option with a 120.4600 exercise price expiring 2028-08-06
Performance stock option underlying shares 12924.0000 shares Underlying common shares for Performance Stock Option (Right to Buy) at 84.6100 exercise price
Performance restricted stock units outstanding 4802.0000 shares Underlying common shares for Performance Restricted Stock Units held directly
Stock Option (Right to Buy) financial
"Security title listed as Stock Option (Right to Buy) for derivative entries"
Restricted Stock Units financial
"Security title reported as Restricted Stock Units with common stock underlying"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Security title shown as Performance Restricted Stock Units with vesting on performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Performance Stock Option (Right to Buy) financial
"Derivative security titled Performance Stock Option (Right to Buy) with 12,924 underlying shares"
Payment of exercise price or tax liability by delivering or withholding securities financial
"Transaction code F described as payment of exercise price or tax liability"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Bio-Techne (TECH) report for Shane Bohnen?

Bio-Techne reported that SVP and General Counsel Shane Bohnen exercised stock options for 448 shares of common stock at 47.6000 per share on 2026-07-23, with an associated option on 448 shares removed from his derivative holdings and 344 shares withheld to cover exercise price or taxes.

How many Bio-Techne (TECH) shares did Shane Bohnen acquire through option exercise?

Shane Bohnen acquired 448 shares of Bio-Techne common stock through the exercise of stock options on 2026-07-23 at an exercise price of 47.6000 per share, converting a derivative position into directly held common stock without any reported open-market purchase or sale.

How many Bio-Techne (TECH) shares were withheld for taxes or exercise price?

To satisfy the exercise price or related tax obligations, 344 shares of Bio-Techne common stock were withheld at a price of 71.7700 per share. This transaction is coded "F," meaning the payment was made by delivering or withholding securities rather than using cash.

What option and stock-unit awards does Shane Bohnen still hold at Bio-Techne (TECH)?

Shane Bohnen continues to hold several equity awards, including stock options over 8,944 underlying shares at a 66.9700 exercise price expiring 2027-08-05 and options over 3,460 underlying shares at 120.4600 expiring 2028-08-06, along with multiple restricted and performance stock units.

Were Shane Bohnen’s Bio-Techne (TECH) transactions made under a Rule 10b5-1 plan?

The Form 4 indicates these transactions were not made under a Rule 10b5-1 trading plan, as the filing’s Rule 10b5-1 checkbox is not marked. No footnote describes any pre-arranged trading arrangement governing this option exercise or the related share withholding.

Did Shane Bohnen sell any Bio-Techne (TECH) shares on the open market in this filing?

No open-market sale is reported. The filing shows an option exercise for 448 shares and a separate withholding of 344 shares to cover exercise price or taxes, but it does not disclose any sale transaction coded as an open-market disposition.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bohnen Shane

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP - General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/23/2026M448A$47.67,697D
Common Stock07/23/2026F344D$71.777,353D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$47.607/23/2026M448 (1)08/07/2026Common Stock448$00D
Stock Option (Right to Buy)$66.97 (1)08/05/2027Common Stock8,9448,944D
Stock Option (Right to Buy)$120.46 (1)08/06/2028Common Stock3,4603,460D
Stock Option (Right to Buy)$94.52 (2)08/15/2029Common Stock3,5083,508D
Stock Option (Right to Buy)$73.76 (3)04/03/2030Common Stock3,9283,928D
Stock Option (Right to Buy)$84.61 (5)08/15/2030Common Stock16,30216,302D
Restricted Stock Units(4) (6) (6)Common Stock4949D
Performance Restricted Stock Units(4) (7) (7)Common Stock4,8024,802D
Performance Stock Option (Right to Buy)$84.61 (7) (7)Common Stock12,92412,924D
Performance Restricted Stock Units(4) (8) (8)Common Stock10,01210,012D
Restricted Stock Units(4) (9) (9)Common Stock3,3383,338D
Stock Option (Right to Buy)$74.91 (10)08/15/2034Common Stock13,48813,488D
Performance Restricted Stock Units(4) (11) (11)Common Stock13,99213,992D
Restricted Stock Units(4) (12) (12)Common Stock6,9966,996D
Stock Option (Right to Buy)$53.6 (13)08/15/2035Common Stock17,89717,897D
Explanation of Responses:
1. Fully exercisable.
2. Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024.
3. Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
4. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
5. Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
6. 49 restricted stock units vest on 8/15/2026.
7. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
8. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
9. 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
10. Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
11. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
12. 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
13. Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
/s/ Andrew Nick as Attorney-in-Fact for Shane Bohnen pursuant to Power of Attorney previously filed.07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)